Alain Algazi, MD
|
Title(s) | Associate Professor, Medicine |
---|
School | School of Medicine |
---|
Address | 550 16th. Street San Francisco CA 94158
|
---|
Phone | 415-353-7552 |
---|
vCard | Download vCard |
---|
|
|
ORNG Applications Bibliographic
Altmetrics Details
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun. 2020 12 07; 11(1):6262.
Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, Hernandez-Aya L, Lawrence D, Lutzky J, Miller WH, Campbell KM, Delafont B, Marshall S, Mueller N, Robert C. PMID: 33288749.
View in: PubMed Mentions: 1 Fields: Translation: HumansCTClinical Trials
-
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568.
PMID: 33020646.
View in: PubMed Mentions: 2 Fields: Translation: HumansCTClinical Trials
-
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Ann Surg Oncol. 2020 Oct; 27(11):4122-4130.
Levine LS, Mahuron KM, Tsai KK, Wu C, Mattis DM, Pauli ML, Oglesby A, Lee JC, Spitzer MH, Krummel MF, Algazi AP, Rosenblum MD, Alvarado M, Daud AI. PMID: 32488521.
View in: PubMed Mentions: Fields:
-
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clin Cancer Res. 2020 06 15; 26(12):2827-2837.
Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino C, Bhatia S, Gargosky S, Andtbacka RHI, Fox BA, Rosenblum MD, Daud AI. PMID: 32376655.
View in: PubMed Mentions: 2 Fields:
-
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 04; 31(4):532-540.
Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI. PMID: 32147213.
View in: PubMed Mentions: 7 Fields:
-
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunol Res. 2020 02; 8(2):246-254.
Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L. PMID: 31852717.
View in: PubMed Mentions: 3 Fields: Translation: HumansCellsCTClinical Trials
-
Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. Am J Clin Dermatol. 2019 Dec; 20(6):781-796.
Oglesby A, Algazi AP, Daud AI. PMID: 31228012.
View in: PubMed Mentions: Fields: Translation: HumansCells
-
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. Pigment Cell Melanoma Res. 2019 07; 32(4):603-606.
Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A. PMID: 30801911.
View in: PubMed Mentions: 2 Fields: Translation: Humans
-
Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer. Laryngoscope. 2020 02; 130(2):E48-E56.
Xu MJ, Plonowska KA, Gurman ZR, Humphrey AK, Ha PK, Wang SJ, El-Sayed IH, Heaton CM, George JR, Yom SS, Algazi AP, Ryan WR. PMID: 30919470.
View in: PubMed Mentions: Fields: Translation: Humans
-
Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. Head Neck. 2019 06; 41(6):E82-E85.
Chan JW, Yeh I, El-Sayed IH, Algazi AP, Glastonbury CM, Ha PK, Yom SS, van Zante A. PMID: 30633411.
View in: PubMed Mentions: 3 Fields: Translation: Humans
-
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with =25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019 01; 107:142-152.
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. PMID: 30576970.
View in: PubMed Mentions: 24 Fields: Translation: HumansCTClinical Trials
-
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-? and IL-12. Immunity. 2018 12 18; 49(6):1148-1161.e7.
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. PMID: 30552023.
View in: PubMed Mentions: 75 Fields: Translation: HumansAnimalsCells
-
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. Am J Clin Oncol. 2018 Nov; 41(11):1083-1088.
Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B. PMID: 29462123.
View in: PubMed Mentions: 20 Fields:
-
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23; 379(8):722-730.
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K. PMID: 30134131.
View in: PubMed Mentions: 157 Fields: Translation: HumansCTClinical Trials
-
Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma. J Otolaryngol Head Neck Surg. 2018 Apr 25; 47(1):28.
Xu MJ, Wu TJ, van Zante A, El-Sayed IH, Algazi AP, Ryan WR, Ha PK, Yom SS. PMID: 29695289.
View in: PubMed Mentions: 2 Fields: Translation: Humans
-
Major prognostic factors for recurrence and survival independent of the American Joint Committee on Cancer eighth edition staging system in patients with cutaneous squamous cell carcinoma treated with multimodality therapy. Head Neck. 2018 07; 40(7):1406-1414.
Xu MJ, Lazar AA, Garsa AA, Arron ST, Ryan WR, El-Sayed IH, George JR, Algazi AP, Heaton CM, Ha PK, Yom SS. PMID: 29524273.
View in: PubMed Mentions: 2 Fields: Translation: Humans
-
High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 01 18; 553(7688):347-350.
PMID: 29320474.
View in: PubMed Mentions: 51 Fields: Translation: HumansCells
-
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 2018 01; 31(1):110-114.
Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A. PMID: 28921907.
View in: PubMed Mentions: 8 Fields: Translation: HumansCTClinical Trials
-
Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). Immunotherapy. 2017 12; 9(16):1309-1321.
Canton DA, Shirley S, Wright J, Connolly R, Burkart C, Mukhopadhyay A, Twitty C, Qattan KE, Campbell JS, Le MH, Pierce RH, Gargosky S, Daud A, Algazi A. PMID: 29064334.
View in: PubMed Mentions: 9 Fields: Translation: HumansAnimals
-
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol. 2017 Dec 20; 35(36):4050-4056.
PMID: 28837405.
View in: PubMed Mentions: 53 Fields: Translation: HumansCTClinical Trials
-
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 Jul 20; 2(14).
PMID: 28724802.
View in: PubMed Mentions: 14 Fields:
-
Are PD-1 antibodies safe for use in metastatic uveal melanoma? Melanoma Manag. 2017 May; 4(2):79-82.
Tsai KK, Algazi AP. PMID: 30190908.
View in: PubMed Mentions:
-
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424.
PMID: 28411193.
View in: PubMed Mentions: 77 Fields: Translation: HumansCellsCTClinical Trials
-
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017 Apr 25; 116(9):1141-1147.
PMID: 28324889.
View in: PubMed Mentions: 25 Fields: Translation: HumansCTClinical Trials
-
Head and neck cancer in 2016: A watershed year for improvements in treatment? Nat Rev Clin Oncol. 2017 Feb; 14(2):76-78.
PMID: 27922045.
View in: PubMed Mentions: 3 Fields: Translation: Humans
-
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clin Cancer Res. 2017 04 15; 23(8):1910-1919.
PMID: 27803065.
View in: PubMed Mentions: 18 Fields: Translation: HumansCTClinical Trials
-
Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst. 2017 01; 109(1).
PMID: 27671684.
View in: PubMed Mentions: 9 Fields:
-
Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016; 4:58.
PMID: 27660712.
View in: PubMed Mentions: 8 Fields:
-
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Nov 15; 122(21):3344-3353.
PMID: 27533448.
View in: PubMed Mentions: 76 Fields: Translation: Humans
-
The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Nov 15; 122(21):3354-3362.
PMID: 27533633.
View in: PubMed Mentions: 56 Fields: Translation: Humans
-
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016 09 01; 126(9):3447-52.
PMID: 27525433.
View in: PubMed Mentions: 124 Fields: Translation: HumansCells
-
NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 08; 14(8):945-58.
PMID: 27496110.
View in: PubMed Mentions: 22 Fields: Translation: Humans
-
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9.
PMID: 27092830.
View in: PubMed Mentions: 254 Fields: Translation: HumansCTClinical Trials
-
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Apr; 14(4):450-73.
PMID: 27059193.
View in: PubMed Mentions: 52 Fields: Translation: Humans
-
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8.
PMID: 26811525.
View in: PubMed Mentions: 91 Fields: Translation: HumansCTClinical Trials
-
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov; 151(11):1206-1212.
PMID: 26222619.
View in: PubMed Mentions: 93 Fields: Translation: Humans
-
Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma. Br J Dermatol. 2015 Aug; 173(2):544-6.
PMID: 25702621.
View in: PubMed Mentions: 6 Fields: Translation: Humans
-
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer. 2015 Apr 14; 112(8):1326-31.
PMID: 25867272.
View in: PubMed Mentions: 6 Fields: Translation: HumansCTClinical Trials
-
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
PMID: 25665005.
View in: PubMed Mentions: 150 Fields: Translation: HumansAnimalsCells
-
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56.
PMID: 25600339.
View in: PubMed Mentions: 90 Fields: Translation: HumansCells
-
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec; 71(6):1102-1109.e1.
PMID: 25440439.
View in: PubMed Mentions: 18 Fields: Translation: Humans
-
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704.
PMID: 25287827.
View in: PubMed Mentions: 63 Fields: Translation: HumansCTClinical Trials
-
Melanoma immunotherapy. . 2014 Jun 01; 15(6):665-74.
PMID: 24651672.
View in: PubMed Mentions:
-
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44.
PMID: 23724846.
View in: PubMed Mentions: 1219 Fields: Translation: HumansCTClinical Trials
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95.
PMID: 23051966.
View in: PubMed Mentions: 233 Fields: Translation: HumansCTClinical Trials
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 11 01; 367(18):1694-703.
PMID: 23020132.
View in: PubMed Mentions: 864 Fields: Translation: HumansCellsCTClinical Trials
-
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012 Jan 03; 106(1):85-91.
PMID: 22127285.
View in: PubMed Mentions: 16 Fields: Translation: HumansCTClinical Trials
-
NRAS-mutant melanoma: response to chemotherapy. Arch Dermatol. 2011 May; 147(5):626-7.
Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI. PMID: 21576590.
View in: PubMed Mentions: 1 Fields: Translation: Humans
-
Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer. 2010 Nov 09; 103(10):1548-53.
DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI. PMID: 20924376.
View in: PubMed Mentions: 4 Fields: Translation: HumansCTClinical Trials
-
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res. 2010 Aug 17; 2:197-211.
Algazi AP, Soon CW, Daud AI. PMID: 21188111.
View in: PubMed Mentions:
-
New horizons in melanoma treatment: targeting molecular pathways. Ochsner J. 2010; 10(2):93-8.
PMID: 21603363.
View in: PubMed Mentions:
-
Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics. 2009 Jul; 6(3):587-97.
Algazi AP, Kadoch C, Rubenstein JL. PMID: 19560747.
View in: PubMed Mentions: 10 Fields: Translation: Humans
-
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 01; 6:22.
Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. PMID: 18452610.
View in: PubMed Mentions: 36 Fields: Translation: HumansCellsCTClinical Trials
-
Lesions of frontal cortex diminish the auditory mismatch negativity. Electroencephalogr Clin Neurophysiol. 1994 Nov; 91(5):353-62.
Alho K, Woods DL, Algazi A, Knight RT, Näätänen R. PMID: 7525232.
View in: PubMed Mentions: 47 Fields: Translation: Humans
-
Processing of auditory stimuli during auditory and visual attention as revealed by event-related potentials. Psychophysiology. 1994 Sep; 31(5):469-79.
Alho K, Woods DL, Algazi A. PMID: 7972601.
View in: PubMed Mentions: 31 Fields: Translation: Humans
-
Stages of auditory feature conjunction: an event-related brain potential study. J Exp Psychol Hum Percept Perform. 1994 Feb; 20(1):81-94.
Woods DL, Alho K, Algazi A. PMID: 8133226.
View in: PubMed Mentions: 15 Fields: Translation: Humans
-
Intermodal selective attention: evidence for processing in tonotopic auditory fields. Psychophysiology. 1993 May; 30(3):287-95.
Woods DL, Alho K, Algazi A. PMID: 8497558.
View in: PubMed Mentions: 13 Fields: Translation: Humans
-
Intermodal selective attention. I. Effects on event-related potentials to lateralized auditory and visual stimuli. Electroencephalogr Clin Neurophysiol. 1992 May; 82(5):341-55.
Woods DL, Alho K, Algazi A. PMID: 1374703.
View in: PubMed Mentions: 34 Fields: Translation: Humans
-
Intermodal selective attention. II. Effects of attentional load on processing of auditory and visual stimuli in central space. Electroencephalogr Clin Neurophysiol. 1992 May; 82(5):356-68.
Alho K, Woods DL, Algazi A, Näätänen R. PMID: 1374704.
View in: PubMed Mentions: 45 Fields: Translation: Humans
-
Brain potential signs of feature processing during auditory selective attention. Neuroreport. 1991 Apr; 2(4):189-92.
Woods DL, Alho K, Algazi A. PMID: 1893092.
View in: PubMed Mentions: 7 Fields: Translation: Humans
This graph shows the total number of publications by year. To see the data as text, click here.
This graph shows the total number of publications by year. To return to the graph, click here.
Year | Publications |
---|
1991 | 1 | 1992 | 2 | 1993 | 1 | 1994 | 3 | 2008 | 1 | 2009 | 1 | 2010 | 3 | 2011 | 2 | 2012 | 2 | 2013 | 1 | 2014 | 3 | 2015 | 5 | 2016 | 11 | 2017 | 7 | 2018 | 7 | 2019 | 5 | 2020 | 5 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs
|
Derived automatically from this person's publications.
_
People in Profiles who have published with this person.
_
People who share similar concepts with this person.
_
Search Department
_
|